UBS Group
BLACR

UBS Group’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

UBS Group’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22
Closed -$2 – 10263
2024
Q2 		$2 Hold
22
– – ﹤0.01% 9427
2024
Q1 		$3 Buy
+22
New +$3 ﹤0.01% 9171
2023
Q4 		– Sell
-5,067
Closed -$1.17K – 10061
2023
Q3 		$1.17K Buy
+5,067
New +$999 ﹤0.01% 8068

Other funds holding BLACR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

UBS Group's BLACR Position: Q3 2024 in Review

UBS Group sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q3 2024, closing a stake of 22 shares — an estimated $2 sold.

UBS Group first reported a position in BLACR in Q3 2023 and held it in 3 quarters. The position peaked at $1.17K in Q3 2023. 28 funds tracked by Wall St. Rank hold BLACR as of Q3 2024.

  • UBS Group reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 22 Bellevue Life Sciences Acquisition Corp. Rights shares in Q3 2024, an estimated $2.
  • UBS Group first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q3 2023 and held it in 3 quarters.
  • UBS Group's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $1.17K in Q3 2023.
  • 28 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.